Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Hand Function Outcome After the Application of Transfer Energy Capacitive and Resistive on Post-burn Patients Presented With Carpal Tunnel Syndrome

NCT07660328 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-06-16
Last updated
2026-06-25

Condition(s) studied

Carpal Tunnel Syndrome (CTS) Post-burn

Investigational drug(s) / intervention(s)

Transfer Energy Capacitive and Resistive (TECAR) [ SMART TECAR }Standard Hand Rehabilitation [ US }

Transfer Energy Capacitive and Resistive (TECAR) [ SMART TECAR }: TECAR therapy at a frequency of 0.5 MHz and intensity of 30 to 50% and medium Capacitive Energy Transfer electrode (60 mm), 5 min capacitive (CAP) and 10 min resistive (RES), The passive electrode was fixed to the dorsum of the hand while the active electrode was moved in a circular manner from the proximal carpal tunnel to the median nerve pathway of the palm in three sessions per week for two weeks

Standard Hand Rehabilitation [ US }: US using a 3 MHz probe at a dose of 1.5 watts/cm2 for 5 min intermittently for 2 weeks, 5 times a week, plus mobility and strengthening exercises

Study summary

Carpal Tunnel Syndrome (CTS) is a common entrapment neuropathy that can develop as a secondary complication following deep burns involving the hand or wrist. Post-burn CTS arises due to factors such as fibrosis, edema, and scar contracture, which may increase pressure on the median nerve within the carpal tunnel, leading to significant pain, sensory disturbances, and impaired hand function Recent studies support the effectiveness of Transfer Energy Capacitive and Resistive (TECAR ) therapy in idiopathic CTS, showing improvements in pain, symptom severity, and function, as measured by validated tools such as the Boston Carpal Tunnel Questionnaire (BCTQ) and Visual Analogue Scale (VAS).

A study reported that both TECAR and ultrasound groups showed significant symptom improvement after treatment, although ultrasound had more sustained effects on median nerve cross-sectional area at 3 months

Eligibility

Sex
ALL
Min age
20 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Participant is between 20 and 40 years of age. * Diagnosed with mild to moderate carpal tunnel syndrome (CTS). * History of an upper limb burn, with the percentage of the Total Body Surface Area (TBSA) ranging from 20% to 25%. * Upper limb burn is diagnosed as a 2nd or 3rd-degree burn complicated with carpal tunnel syndrome. * Carpal tunnel syndrome diagnosis is clinically confirmed using physical examination, including a positive Tinel's sign and positive Phalen's test. * Participant provides written informed consent before enrollment. Exclusion Criteria: * History of double crush syndrome, cervical radiculopathy, or fibromyalgia. * History of wrist fracture or distal radius fracture. * Diagnosis of systemic or local diseases that contribute to peripheral neuropathy, including Diabetes Mellitus or rheumatoid arthritis (RA). * Diagnosis of hypothyroidism, skin diseases, or peripheral vascular diseases. * Current or past history of cancer. * Use of a hand or wrist splint within the past three months. * Presence of an implanted pacemaker or electrical prosthesis.

Primary outcome measure(s)

  • Symptom Severity — Baseline and 2 weeks
    The Arabic version of the BCTQ-SSS will be used to self-report symptom severity. It consists of 11 items assessing pain, numbness, paresthesia, weakness, and nocturnal symptoms. Each item is scored from 1 (never/none) to 5 (most severe). The overall score is calculated as the mean of the items, ranging from 1 to 5, where higher scores indicate worse symptom severity.
  • Functional Status — Baseline and 2 weeks.
    The Arabic version of the BCTQ-FSS will be used to evaluate hand function across 8 common activities. Each activity is scored from 1 (no difficulty) to 5 (cannot perform the activity at all). The total score is the mean of the items, ranging from 1 to 5, where higher scores represent greater functional impairment.
  • Grip Strength — Baseline and 2 weeks.
    Objective hand function and force production of the median nerve-innervated muscles will be measured using a Camry Digital Handgrip Dynamometer. Measurements are recorded in kilograms (kg), up to a maximum strength of 90 kg. Higher scores indicate greater hand grip strength.

Trial sites (1)

FacilityCityRegionStatus
QWAM physio clinic Al Mansurah Mansoura
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07660328 on ClinicalTrials.gov ↗ ← All trials in Egypt